2026 Q1 -tulosraportti
Vain PDF
51 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 17.2. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·19 t sittenInvesttech 01.07.2026: Short term: Intervacc is in a rising trend channel in the short term. This shows that investors over time have bought at increasingly higher prices to get into the stock and indicates a good development for the company. The stock has broken up through the resistance at approximately 1.30 kronor. Further upside is thus signaled, and there is now support at 1.30 kronor in case of reactions back. Volume tops and volume bottoms correspond well with tops and bottoms in the price. The volume balance is also positive, which strengthens the trend picture. The stock is considered technically positive overall in the short term. Recommendation one to six weeks' horizon: Buy (Score: 97) Medium term: Intervacc has broken down through the floor of a rising trend channel in the medium term. This initially indicates a weaker rate of increase, or the initiation of a more horizontal development. The stock has broken up through the resistance at approximately 1.28 kronor. Further upside is thus signaled, and there is now support at 1.28 kronor in case of reactions back. The volume balance is positive and strengthens the stock in the short term. The stock is considered technically positive overall in the medium term. Recommendation one to six months' horizon: Buy (Score: 88) Long term: Intervacc has broken up through the ceiling of a falling trend channel in the long term. This initially indicates a weaker rate of decline, or the initiation of a more horizontal development. The stock gave a buy signal from a double-bottom formation upon breaking up through the resistance at 1.19 kronor. Further upside to 1.70 kronor or more is signaled. The stock has marginally broken up through the resistance at approximately 1.30 kronor. An established break will indicate further upside. Volume tops and volume bottoms correspond well with tops and bottoms in the price. The volume balance is also positive, which strengthens the stock. The RSI curve shows a rising trend, which can be an early signal for the initiation of a rising trend for the price as well. The stock is considered technically positive overall in the long term. Recommendation one to six quarters' horizon: Buy (Score: 87) Total analysis: Intervacc is technically positive in the short, medium, and long term. The stock is maximally positive on insider trades. Recommendation one to six months' horizon: Buy (Score: 97)- 15.5.Sales in Q1 came in well below our expectations, particularly outside Sweden. Awareness of both equine strangles and Strangvac appears to be developing more slowly than we had expected. While this leads us to lower our forecasts, progress in the US regulatory process continues and our confidence in a potential 2027 approval is thus increasing. Following the Q1 report, we lower our fair value slightly to SEK1.8–2.4 (1.9–2.5) per share. Disappointing sales. Revenues in Q1 were down by 26% Y/Y to SEK3.4m, well below our forecast of SEK8.6m. Sweden was the bright spot with a strong increase in doses delivered, although this was offset by significantly weaker UK sales, which we believe partly reflected the absence of a promotional campaign like the one run by Dechra last year. However, opex was broadly in line with our expectations, although impacted by SEK5.2m in one-off items related to the CEO transition. Despite a significant loss for the period of SEK21.7m, the financial position remains solid, in our view, and we do not see any near-term need for additional capital. US study progressing. Awareness of equine strangles appears to be very low still in Europe. To support disease and therapy awareness, the company held a KOL meeting in Edinburgh in April. While unlikely to materially affect near-term sales, such initiatives remain important for building long-term demand. By comparison, we believe the US market appears more receptive to strangles vaccination, making progress in the regulatory process increasingly important for the equity story. The clinical programme continues to advance, with more than 100 of the planned 600 horses enrolled in the ongoing safety study, which Intervacc expects to be completed in Q3. Estimate changes. We have considerably reduced our sales forecasts, as awareness-building around equine strangles appears to be more challenging in Europe than we previously thought. Fair value lowered. To reflect the equity story becoming somewhat more back-end loaded, we lower our fair value to SEK1.8–2.4 per share. https://mfn.se/a/carnegie/intervacc-us-progress-while-european-sales-still-soft-q1-review
The question is what it takes for Strangvac to break through. Broader awareness? Difficult and takes time. Regulatory decisions? Difficult and largely beyond Intervacc's control. USA? A long way to go, but with continued progress. Iceland was indeed a step in the right direction, as well as increased sales in Sweden. Expected more, but not much at all. Hoping for a better remaining 2026. - ·16.4.The decision in Iceland is indeed a really great endorsement for Strangvac, despite the fact that the number of horses might not be a monster figure. An incredibly strong selling point as well as progress. What do you think?
One of many positive news recently. I have been waiting a long time for a turnaround and the feeling is that the wait is now over. 
·30.3.How can this be possible -6.56%, Intervacc has announced a significant breakthrough and becomes the first in the world to demonstrate a vaccine that protects piglets from virulent Streptococcus suis (S.Yes, it's crazy that you can trade the stock at the same level as a year and a half ago, many good news have come since then. We simply have to be glad that it's possible to trade at this level because sooner or later the stock surge will come.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
51 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·19 t sittenInvesttech 01.07.2026: Short term: Intervacc is in a rising trend channel in the short term. This shows that investors over time have bought at increasingly higher prices to get into the stock and indicates a good development for the company. The stock has broken up through the resistance at approximately 1.30 kronor. Further upside is thus signaled, and there is now support at 1.30 kronor in case of reactions back. Volume tops and volume bottoms correspond well with tops and bottoms in the price. The volume balance is also positive, which strengthens the trend picture. The stock is considered technically positive overall in the short term. Recommendation one to six weeks' horizon: Buy (Score: 97) Medium term: Intervacc has broken down through the floor of a rising trend channel in the medium term. This initially indicates a weaker rate of increase, or the initiation of a more horizontal development. The stock has broken up through the resistance at approximately 1.28 kronor. Further upside is thus signaled, and there is now support at 1.28 kronor in case of reactions back. The volume balance is positive and strengthens the stock in the short term. The stock is considered technically positive overall in the medium term. Recommendation one to six months' horizon: Buy (Score: 88) Long term: Intervacc has broken up through the ceiling of a falling trend channel in the long term. This initially indicates a weaker rate of decline, or the initiation of a more horizontal development. The stock gave a buy signal from a double-bottom formation upon breaking up through the resistance at 1.19 kronor. Further upside to 1.70 kronor or more is signaled. The stock has marginally broken up through the resistance at approximately 1.30 kronor. An established break will indicate further upside. Volume tops and volume bottoms correspond well with tops and bottoms in the price. The volume balance is also positive, which strengthens the stock. The RSI curve shows a rising trend, which can be an early signal for the initiation of a rising trend for the price as well. The stock is considered technically positive overall in the long term. Recommendation one to six quarters' horizon: Buy (Score: 87) Total analysis: Intervacc is technically positive in the short, medium, and long term. The stock is maximally positive on insider trades. Recommendation one to six months' horizon: Buy (Score: 97)
- 15.5.Sales in Q1 came in well below our expectations, particularly outside Sweden. Awareness of both equine strangles and Strangvac appears to be developing more slowly than we had expected. While this leads us to lower our forecasts, progress in the US regulatory process continues and our confidence in a potential 2027 approval is thus increasing. Following the Q1 report, we lower our fair value slightly to SEK1.8–2.4 (1.9–2.5) per share. Disappointing sales. Revenues in Q1 were down by 26% Y/Y to SEK3.4m, well below our forecast of SEK8.6m. Sweden was the bright spot with a strong increase in doses delivered, although this was offset by significantly weaker UK sales, which we believe partly reflected the absence of a promotional campaign like the one run by Dechra last year. However, opex was broadly in line with our expectations, although impacted by SEK5.2m in one-off items related to the CEO transition. Despite a significant loss for the period of SEK21.7m, the financial position remains solid, in our view, and we do not see any near-term need for additional capital. US study progressing. Awareness of equine strangles appears to be very low still in Europe. To support disease and therapy awareness, the company held a KOL meeting in Edinburgh in April. While unlikely to materially affect near-term sales, such initiatives remain important for building long-term demand. By comparison, we believe the US market appears more receptive to strangles vaccination, making progress in the regulatory process increasingly important for the equity story. The clinical programme continues to advance, with more than 100 of the planned 600 horses enrolled in the ongoing safety study, which Intervacc expects to be completed in Q3. Estimate changes. We have considerably reduced our sales forecasts, as awareness-building around equine strangles appears to be more challenging in Europe than we previously thought. Fair value lowered. To reflect the equity story becoming somewhat more back-end loaded, we lower our fair value to SEK1.8–2.4 per share. https://mfn.se/a/carnegie/intervacc-us-progress-while-european-sales-still-soft-q1-reviewThe question is what it takes for Strangvac to break through. Broader awareness? Difficult and takes time. Regulatory decisions? Difficult and largely beyond Intervacc's control. USA? A long way to go, but with continued progress. Iceland was indeed a step in the right direction, as well as increased sales in Sweden. Expected more, but not much at all. Hoping for a better remaining 2026.
- ·16.4.The decision in Iceland is indeed a really great endorsement for Strangvac, despite the fact that the number of horses might not be a monster figure. An incredibly strong selling point as well as progress. What do you think?One of many positive news recently. I have been waiting a long time for a turnaround and the feeling is that the wait is now over.
- ·30.3.How can this be possible -6.56%, Intervacc has announced a significant breakthrough and becomes the first in the world to demonstrate a vaccine that protects piglets from virulent Streptococcus suis (S.Yes, it's crazy that you can trade the stock at the same level as a year and a half ago, many good news have come since then. We simply have to be glad that it's possible to trade at this level because sooner or later the stock surge will come.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 17.2. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
51 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 17.2. | ||
2025 Q3 -tulosraportti 19.11.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·19 t sittenInvesttech 01.07.2026: Short term: Intervacc is in a rising trend channel in the short term. This shows that investors over time have bought at increasingly higher prices to get into the stock and indicates a good development for the company. The stock has broken up through the resistance at approximately 1.30 kronor. Further upside is thus signaled, and there is now support at 1.30 kronor in case of reactions back. Volume tops and volume bottoms correspond well with tops and bottoms in the price. The volume balance is also positive, which strengthens the trend picture. The stock is considered technically positive overall in the short term. Recommendation one to six weeks' horizon: Buy (Score: 97) Medium term: Intervacc has broken down through the floor of a rising trend channel in the medium term. This initially indicates a weaker rate of increase, or the initiation of a more horizontal development. The stock has broken up through the resistance at approximately 1.28 kronor. Further upside is thus signaled, and there is now support at 1.28 kronor in case of reactions back. The volume balance is positive and strengthens the stock in the short term. The stock is considered technically positive overall in the medium term. Recommendation one to six months' horizon: Buy (Score: 88) Long term: Intervacc has broken up through the ceiling of a falling trend channel in the long term. This initially indicates a weaker rate of decline, or the initiation of a more horizontal development. The stock gave a buy signal from a double-bottom formation upon breaking up through the resistance at 1.19 kronor. Further upside to 1.70 kronor or more is signaled. The stock has marginally broken up through the resistance at approximately 1.30 kronor. An established break will indicate further upside. Volume tops and volume bottoms correspond well with tops and bottoms in the price. The volume balance is also positive, which strengthens the stock. The RSI curve shows a rising trend, which can be an early signal for the initiation of a rising trend for the price as well. The stock is considered technically positive overall in the long term. Recommendation one to six quarters' horizon: Buy (Score: 87) Total analysis: Intervacc is technically positive in the short, medium, and long term. The stock is maximally positive on insider trades. Recommendation one to six months' horizon: Buy (Score: 97)
- 15.5.Sales in Q1 came in well below our expectations, particularly outside Sweden. Awareness of both equine strangles and Strangvac appears to be developing more slowly than we had expected. While this leads us to lower our forecasts, progress in the US regulatory process continues and our confidence in a potential 2027 approval is thus increasing. Following the Q1 report, we lower our fair value slightly to SEK1.8–2.4 (1.9–2.5) per share. Disappointing sales. Revenues in Q1 were down by 26% Y/Y to SEK3.4m, well below our forecast of SEK8.6m. Sweden was the bright spot with a strong increase in doses delivered, although this was offset by significantly weaker UK sales, which we believe partly reflected the absence of a promotional campaign like the one run by Dechra last year. However, opex was broadly in line with our expectations, although impacted by SEK5.2m in one-off items related to the CEO transition. Despite a significant loss for the period of SEK21.7m, the financial position remains solid, in our view, and we do not see any near-term need for additional capital. US study progressing. Awareness of equine strangles appears to be very low still in Europe. To support disease and therapy awareness, the company held a KOL meeting in Edinburgh in April. While unlikely to materially affect near-term sales, such initiatives remain important for building long-term demand. By comparison, we believe the US market appears more receptive to strangles vaccination, making progress in the regulatory process increasingly important for the equity story. The clinical programme continues to advance, with more than 100 of the planned 600 horses enrolled in the ongoing safety study, which Intervacc expects to be completed in Q3. Estimate changes. We have considerably reduced our sales forecasts, as awareness-building around equine strangles appears to be more challenging in Europe than we previously thought. Fair value lowered. To reflect the equity story becoming somewhat more back-end loaded, we lower our fair value to SEK1.8–2.4 per share. https://mfn.se/a/carnegie/intervacc-us-progress-while-european-sales-still-soft-q1-reviewThe question is what it takes for Strangvac to break through. Broader awareness? Difficult and takes time. Regulatory decisions? Difficult and largely beyond Intervacc's control. USA? A long way to go, but with continued progress. Iceland was indeed a step in the right direction, as well as increased sales in Sweden. Expected more, but not much at all. Hoping for a better remaining 2026.
- ·16.4.The decision in Iceland is indeed a really great endorsement for Strangvac, despite the fact that the number of horses might not be a monster figure. An incredibly strong selling point as well as progress. What do you think?One of many positive news recently. I have been waiting a long time for a turnaround and the feeling is that the wait is now over.
- ·30.3.How can this be possible -6.56%, Intervacc has announced a significant breakthrough and becomes the first in the world to demonstrate a vaccine that protects piglets from virulent Streptococcus suis (S.Yes, it's crazy that you can trade the stock at the same level as a year and a half ago, many good news have come since then. We simply have to be glad that it's possible to trade at this level because sooner or later the stock surge will come.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt